A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN (VBIR) FOR PROSTATE CANCER (PF-06753512)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Pfizer, Inc.
Start Date
July 1, 2016
End Date
December 31, 2021
Administered By
Duke Cancer Institute
Awarded By
Pfizer, Inc.
Start Date
July 1, 2016
End Date
December 31, 2021